JP2005524696A5 - - Google Patents

Download PDF

Info

Publication number
JP2005524696A5
JP2005524696A5 JP2003587800A JP2003587800A JP2005524696A5 JP 2005524696 A5 JP2005524696 A5 JP 2005524696A5 JP 2003587800 A JP2003587800 A JP 2003587800A JP 2003587800 A JP2003587800 A JP 2003587800A JP 2005524696 A5 JP2005524696 A5 JP 2005524696A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
disease
compound
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003587800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005524696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/001556 external-priority patent/WO2003091241A1/en
Publication of JP2005524696A publication Critical patent/JP2005524696A/ja
Publication of JP2005524696A5 publication Critical patent/JP2005524696A5/ja
Withdrawn legal-status Critical Current

Links

JP2003587800A 2002-04-26 2003-04-15 Nr2bレセプターアンタゴニストとしての3,4−ジヒドロキノリン−2(1h)−オン化合物。 Withdrawn JP2005524696A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37593902P 2002-04-26 2002-04-26
PCT/IB2003/001556 WO2003091241A1 (en) 2002-04-26 2003-04-15 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists

Publications (2)

Publication Number Publication Date
JP2005524696A JP2005524696A (ja) 2005-08-18
JP2005524696A5 true JP2005524696A5 (enExample) 2006-06-08

Family

ID=29270728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003587800A Withdrawn JP2005524696A (ja) 2002-04-26 2003-04-15 Nr2bレセプターアンタゴニストとしての3,4−ジヒドロキノリン−2(1h)−オン化合物。

Country Status (15)

Country Link
US (1) US6713490B2 (enExample)
EP (1) EP1499606B8 (enExample)
JP (1) JP2005524696A (enExample)
AR (1) AR039663A1 (enExample)
AT (1) ATE325117T1 (enExample)
AU (1) AU2003219398A1 (enExample)
BR (1) BR0309778A (enExample)
CA (1) CA2483636A1 (enExample)
DE (1) DE60305026T2 (enExample)
ES (1) ES2258716T3 (enExample)
MX (1) MXPA04010549A (enExample)
PA (1) PA8572601A1 (enExample)
TW (1) TW200406402A (enExample)
UY (1) UY27776A1 (enExample)
WO (1) WO2003091241A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
MXPA06003748A (es) * 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
WO2005097782A1 (ja) * 2004-04-07 2005-10-20 Kyowa Hakko Kogyo Co., Ltd. ピペリジン誘導体
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
CN102223791A (zh) 2008-09-27 2011-10-19 塔阿克斯有限公司 用于神经病变治疗的局部用制剂
WO2010113109A1 (en) * 2009-03-31 2010-10-07 Link Research & Grants Corporation Treatment of tinnitus and associated auditory dysfunctions
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
EP2621475A1 (en) 2010-10-02 2013-08-07 Link Research&Grants Corporation Treatment of tinnitus and related auditory dysfunctions
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
CA2080475C (en) 1990-05-10 2001-04-17 Bertrand Leo Chenard Neuroprotective indolone and related derivatives
DE69309297T2 (de) 1992-10-30 1997-07-03 Pfizer Neuroprotektive 3,4-dihydro-2(1h)-chinolone
PA8525601A1 (es) 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol

Similar Documents

Publication Publication Date Title
JP2005524696A5 (enExample)
JP2010529203A5 (enExample)
RU2006128446A (ru) Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора
KR102309973B1 (ko) 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물
JP2006022107A5 (enExample)
JP2019524822A5 (enExample)
KR20170122820A (ko) 비정상적 불수의 운동 장애의 치료 방법
JP2014511892A5 (enExample)
EA016687B8 (ru) Производные циклопропиламида
JP2013526609A5 (enExample)
EP2279727A3 (en) Nanoparticulate aripiprazole formulations
JP2009510044A5 (enExample)
SG166125A1 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease
JP2011510014A5 (enExample)
RU2016131875A (ru) Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы
JP2010527993A5 (enExample)
HRP20120876T1 (hr) Brzo disocirajuä†i antagonisti dopamin 2 receptora
JP7583895B2 (ja) 外傷性脳損傷を検出するための組成物および方法
US10647679B2 (en) N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto
JP2016513691A5 (enExample)
JP2004536111A5 (enExample)
JP2013515040A5 (enExample)
RU2015148927A (ru) Производные изохинолина, стимулирующие нейрогенез
JP2012532858A5 (enExample)
BR0309778A (pt) Compostos 3,4-di-hidroquinolin-2(1h)-ona como antagonistas do receptor nr2b